PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER), 3. POSTER: Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer (ESGO Encore), 1. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. 11. #NMQFLeadershipSummit, The next @DEAHQ's National Prescription Drug #TakeBackDay will be held on Saturday, April 22! We're taking on some of the biggest healthcare challenges in . ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1?specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E), 19. 4. GSK has a global collaboration with Alector in immuno-neurology for neurodegenerative diseases, an area of . Gibbons D, Marijam A, Symons JM, et al. Our market sites can be reached by visiting our location selector. Single-agent Belantamab Mafodotin for RRMM: Analysis of the Lyophilized Presentation Cohort from the Pivotal DREAMM-2 Study [Poster not available for viewing due to copyright restrictions], 9. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright), 4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission), 5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). 60 ), 2. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients? Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. 7. Bogart M, Germain G, Lalibert F, et al. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. Nat Med. Coyne, D et al. #ppswgg#myoldmedss#safedisposallz, Real conversations generate impactful change. Vogelmeier CF, Boucot IH, Kerwin EM, et al. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. 2017;35(15):suppl TPS3113. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 14. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics [Poster not available for viewing due to copyright restrictions], 8. GSK values your privacy and your trust is important to us. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. By clicking this link, you will be taken to a website that is independent from GSK. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. 178 Medical Affairs Jobs in London, England, United Kingdom (9 new) Regulatory Affairs Officer / RAQA Officer Hays Uxbridge, England, United Kingdom Be an early applicant 4 weeks ago. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. POSTER: Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real world single center experience (Presentation Is Not Available Due to Copyright), 7. We set an aspirational goal here in the US. POSTER: Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability?high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study, 5. Genes Dev. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. 8. CAPTAIN: Effects of age as a continuous variable on asthma control. POSTER: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs), 10. Kerwin EM, Maltais F, Boucot IH, et al. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin? ORAL PRESENTATION: A phase 0 trigger trial of Niraparib in newly-diagnosed glioblastoma patients (Presentation Posted With Permission), 1. 340), 1. GSK3377794 is an adoptive cell therapy that uses genetically engineered autologous T cells expressing NY-ESO-1? POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study, 9. Silver J, Steffens A, Chastek B, et al. Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. P372; Abstract A6482]. POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. 2. Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial? Communication with Patients/Parents on MenB Vaccination for Older Adolescents and Young Adults. We are sorry for the inconvenience. 7. POSTER: Patient-reported outcomes from the GARNET trial in patients with advanced or recurrent mismatch repair deficient colorectal cancer: a post hoc subgroup analysis, 11. ur employees and our values are at the heart of everything we do. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. POSTER: Two-Year Follow-Up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-? ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies, April 10-15, 2021 and May 17-21, 2021 | Virtual, 1. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. JASPER: Efficacy and Safety of First-Line (1L) Niraparib Plus a Programmed Death Receptor-1 Inhibitor (PD-1i) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), 6. Cookies will only be set if you choose to accept them. Cho E-Y, Cho J-E, Jang S-H, et al. ABSTRACT ONLY: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. and/or LAGE-1a?positive solid tumors, NSCLC, and relapsed/refractory multiple myeloma. Poster No. Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. GSK Medical Affairs A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. 149 Gsk Medical Affairs Jobs in United States (6 new) - LinkedIn POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. 2. 6. Ci 1. Anderson M, Drummond MB, Jain R, et al. There is always room to grow as a professional and own your career path. 1. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4. 2016;126(7):2404-2411. Immune checkpoints and their inhibition in cancer and infectious diseases. [Poster No. 6. P1448. and physicians? Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs). Singh AK, et al. Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma, 2. 1. GSK. PO1437, Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. Prazma C, Bernstein D, Brightling C, et al. 1-800-822-7967. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. 2. Fowler A, Kerstjens HAM, Bailes Z, et al. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. 2013;62(4):773-785. Find out more: gsk.to/41zwzb7, While everyone can be impacted by #myelofibrosis, certain risk factors can increase the likelihood that a person will develop it. para nos informar sobre o problema. 64), 5. P1501. DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and HR-QoL in Patients With RRMM [Poster not available for viewing due to copyright restrictions], 10. Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma, 5. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. 5. Patient Experience Information (PEI) and Patient Involvement in Health Technology Assessment (HTA) Processes in 7 European Countries Using Immuno-Oncology Examples: How Can the Patient Voice Make an Impact? When expanded it provides a list of search options that will switch the search inputs to match the current selection. om ons te informeren over dit probleem. 6. 2018;22(6):527-545. We use cookies to personalise content and ads, to provide social media features and to analyse our websites. . Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations. 61), 1. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. 2. The estimated total pay for a Medical Science Liaison at GSK is $234,850 per year. PUBLICATION ONLY: Qualitative Patient Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma (mSS), 28. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. [Poster No. POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting ?2-agonist therapy. The winners found large companies with a big Hispanic workforce and created solutions including an employer caregiver toolkit and caretaker programs. PUBLICATION ONLY: Efficacy and Safety of Third-line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review, 13. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. 1467. Visit Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. Bogart M, Han X, Bengtson L, et al. The response(s) are not intended to offer recommendations for administering this product in a manner inconsistent with its approved labeling. Trade marks are owned by or licensed to the GSK group of companies. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. 7. 518; Abstract A4579]. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Lu E, et al. A Nationwide Multicentric Study, 4. Sign In. 4. 1. [Poster No. Gupte R, Liu Z, Kraus WL. You are using an unsupported browser.Some features of this site may not function properly. Time-Dependent Covariate Analysis of Hemoglobin Values ?on Risk of MACE in the ASCEND Trials. 373. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. enva un correo electrnico a The estimated base pay is $154,315 per year. Working closely with our employee resource groups, we launched the Accelerating Difference - Ethnic Diversity development program. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. , Have you heard of #myelofibrosis, a rare form of blood cancer? Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial? Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19. Blake SJ, Stannard K, Liu J, et al. Chapman KR, Bosnic-Anticevich S, Cano MC, et al. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. [Poster No. Nous sommes dsols pour la gne occasionne. 1. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. perspective on the burden of Hypereosinophilic Syndrome. Therapeutic Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial? 6. 5. Gibbons D, Marijam A, Morel Symons J, et al. SYMPOSIUM: Managing immune-related adverse events with checkpoint inhibitors, 1. ?trap") fused via a flexible linker to the C-terminus of each heavy chain of the IgG1 antibody blocking PD-L1. Assessment of Asthma Control in Respiratory Specialist Offices in the US. Aydanos a proteger Glassdoor verificando que eres una persona real. You will now be taken from the GSK U.S. Medical Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. Use of Mepolizumab among Individuals with Asthma in the U.S. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. PO0465, 4. Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. Poster with Audio: Voice Recording: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm, Investigating the Role of Eosinophils in Health, Airway Diseases, and Hypereosinophilic Disorders, Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease, Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19), Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pathogenesis, Diagnosis, and Management, The Role of Eosinophilic and Their Potential Heterogeneity in Airways Disease, Uncontrolled Asthma: Changing the Patient Experience, SYMPOSIUM: Advances in Targeting of B-cell Maturation Antigen (BCMA) as an Investigational Novel Approach in Multiple Myeloma, 1. 1. 2017;31(2):101-1261. Easy Apply 1 day ago 25 days annual leave + bank holidays + 3 days off for Christmas + Birthday day-off. Ismaila A, Haeussler K, Czira A, et al. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility. 1. POSTER: Real-World Trends of PARPi Maintenance Treatment Uptake and Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC) in the US, 8. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. Hwee J, Smith S, Small M, et al. Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population. Gsk Medical Affairs Jobs in United States, Director of Medical and Clinical Affairs for Flu/COVID-19 Vaccines, Director, US Medical Affairs, Scientific Affairs and Public Health, Director, Vaccines Scientific Communications, ViiV (GSK) Global Medical Affairs Director, Field Based Medical Science Liaison- IL/MI, Vaccine Development Leader (VDL), MAPS Vaccine, Global Regulatory Affairs Manager, Labelling, Director, Independent Medical Education (IME) & Grants, US Medical Affairs Scientific Director, Specialty Pipeline, ViiV (GSK) Director, Community Medical Liaison, Community Engagement Specialist HIV Prevention, Global Medical Affairs Director - Neurosciences. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. 2. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. 1. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. PUBLICATION ONLY: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma: DREAMM-14, 1. excuses voor het ongemak. Bogart M, Chastek B, White J, et al. 2. envie um e-mail para Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Sort by: relevance - date. Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. and Physicians? Cobolimab is a humanized TIM-3 antagonist immunoglobulin G4 (IgG4) mAb being investigated as a monotherapy and in combination with dostarlimab and TSR-033 in advanced solid tumors, including melanoma, NSCLC, and colorectal cancer. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. GSK6097608 inhibits the binding of CD96 to CD155 and activates T cells and NK cells, which enhances antitumor activity. 2017;47(5):765-779. ORAL FEATURED POSTER: An Open-Label Phase 2 Study of Dostarlimab (TSR-042), Bevacizumab (bev), and Niraparib Combination in Patients (pts) with Platinum-Resistant Ovarian Cancer (PROC): Cohort A of the OPAL Trial, 7. We expect our organization to represent the population we serve by leveraging qualified, talented individuals who represent a variety of ethnicities, genders, disabilities, ages and sexual orientations. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. POSTER: Utility of circulating tumor DNA in breast cancer clinical research and practice: systematic review and meta-analysis, 2. Keeley T, et al. . Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. Real-World Effectiveness of Belimumab in Patients With SLE in the US, 1. Real-World Impact of Systemic Corticosteroid (SCS) Exposure on Healthcare Resource Utilization (HRU) due to SCS-Related Complication among Patients with Asthma in the US? The information is not intended as medical advice. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-6 Study: What Side Effects Were Experienced When Patients With Multiple Myeloma Were Treated With Belantamab Mafodotin in Combination With Another Anti-Myeloma Treatment, Bortezomib/Dexamethasone? J Clin Invest. GSK Montes de Oca R, Bhattacharya S, Vitali N, et al. Poster No. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment (Encore), 3. Browse the 20 Medical Director Jobs at Glaxosmithkline and find out what best fits your career goals. Association between TGF-? Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. Silver J, Bogart M, Molfino N, et al. [Poster No. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). Desrosiers M, Diamant Z, Castelnuovo P, et al. Moore WC, Kornmann O, Humbert M, et al. POSTER: Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 5. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 15. [Poster No. Can Recombinant Zoster Vaccine Administration Decrease the Use of HZ-Related Pain Medication Across Randomized Controlled Studies? Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. P787; Abstract A5625]. 6. Zejula [summary of product characteristics]. GSK Medical Affairs Salaries | Glassdoor Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Ismaila A, Czira A, Haeussler K, et al. 2. ASCEND program: efficacy and safety from ASCEND-D and ?ND, and overall MACE findings, 1. [Poster No. POSTER: Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study (IGCS ENCORE), 1.POSTER: AGO-OVAR 28 / ENGOT-ov57: Niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Presentation Posted With Permission), 2.POSTER: Characterization of long term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO / A-AGO (Presentation Posted With Permission), 3.POSTER: Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (Presentation Posted With Permission), 1. 5. Poster No. 3. Oncotarget. POSTER: Master protocol to assess the safety and recommended phase 2 dose of next generation NY-ESO-1?specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer, 1. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. 5. Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment [Poster not available for viewing due to copyright restrictions], 2. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Pomalidomide and Dexamethasone (B-Pd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 10. 1. Singh, AK et al. Rothnie KJ, Bancroft T, Bogart M, et al. Singh AK, et al. 3. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. Poster No. Apprentice programmes Kickstart a brilliant career with hands-on experience from day one.